SG11201804263PA - Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor - Google Patents
Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitorInfo
- Publication number
- SG11201804263PA SG11201804263PA SG11201804263PA SG11201804263PA SG11201804263PA SG 11201804263P A SG11201804263P A SG 11201804263PA SG 11201804263P A SG11201804263P A SG 11201804263PA SG 11201804263P A SG11201804263P A SG 11201804263PA SG 11201804263P A SG11201804263P A SG 11201804263PA
- Authority
- SG
- Singapore
- Prior art keywords
- bothell
- drive
- international
- washington
- fucose
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- SQTFKIKSQNCWGJ-KCDKBNATSA-N (2s,3r,4r,5s)-2-fluoro-3,4,5-trihydroxyhexanal Chemical compound C[C@H](O)[C@@H](O)[C@@H](O)[C@H](F)C=O SQTFKIKSQNCWGJ-KCDKBNATSA-N 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title abstract 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000007943 implant Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263228P | 2015-12-04 | 2015-12-04 | |
| US201662308583P | 2016-03-15 | 2016-03-15 | |
| US201662321857P | 2016-04-13 | 2016-04-13 | |
| PCT/US2016/064783 WO2017096274A1 (en) | 2015-12-04 | 2016-12-02 | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804263PA true SG11201804263PA (en) | 2018-06-28 |
Family
ID=58797961
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804263PA SG11201804263PA (en) | 2015-12-04 | 2016-12-02 | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor |
| SG10202005298RA SG10202005298RA (en) | 2015-12-04 | 2016-12-02 | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202005298RA SG10202005298RA (en) | 2015-12-04 | 2016-12-02 | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180353524A1 (enExample) |
| EP (1) | EP3383404A4 (enExample) |
| JP (1) | JP6906520B2 (enExample) |
| KR (1) | KR20180086233A (enExample) |
| CN (1) | CN108289903B (enExample) |
| AU (1) | AU2016362993A1 (enExample) |
| BR (1) | BR112018011261A2 (enExample) |
| CA (1) | CA3005997A1 (enExample) |
| EA (1) | EA201891340A1 (enExample) |
| IL (1) | IL259479B (enExample) |
| MX (1) | MX385283B (enExample) |
| SG (2) | SG11201804263PA (enExample) |
| WO (1) | WO2017096274A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012019165A2 (en) | 2010-08-05 | 2012-02-09 | Seattle Genetics, Inc. | Methods of inhibition of protein fucosylation in vivo using fucose analogs |
| CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| IL271012B2 (en) * | 2017-06-07 | 2023-12-01 | Seagen Inc | T cells with reduced surface fucosylation and methods for their preparation and use |
| WO2019075449A1 (en) * | 2017-10-13 | 2019-04-18 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | FUCOSYLATION AND IMMUNOSURVEILLANCE OF MELANOMA |
| AU2019324170A1 (en) | 2018-08-23 | 2021-02-18 | Seagen, Inc. | Anti-TIGIT antibodies |
| JP2022514299A (ja) * | 2018-12-19 | 2022-02-10 | シージェン インコーポレイテッド | 抗体の制御されたフコシル化 |
| WO2021034774A1 (en) * | 2019-08-16 | 2021-02-25 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Fucosylation and immune modulation in cancer |
| CN111973749B (zh) * | 2020-09-07 | 2023-03-21 | 威海人生药业集团股份有限公司 | 一种抗肿瘤免疫治疗的药物组合物 |
| US12036286B2 (en) | 2021-03-18 | 2024-07-16 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| WO2022221766A1 (en) * | 2021-04-16 | 2022-10-20 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Fucosylation and immune modulation in cancer |
| CN113274502B (zh) * | 2021-05-05 | 2023-01-03 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 用于特定型三阴乳腺癌免疫治疗的组合物 |
| US20240238318A1 (en) * | 2021-05-06 | 2024-07-18 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | L-fucose and anti-androgen receptor therapy for treatment of cancer |
| CN113413465B (zh) * | 2021-06-15 | 2022-06-03 | 北京大学 | 岩藻糖基化抑制剂在抗癌导致炎症中的应用 |
| CN115466297B (zh) * | 2022-08-25 | 2023-07-07 | 青岛农业大学 | L-岩藻糖的应用以及动物饲料 |
| WO2024077106A2 (en) * | 2022-10-04 | 2024-04-11 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Leveraging l-fucose-mediated signaling to induce monocyte-derived dendritic cell polarization |
| WO2024191807A1 (en) | 2023-03-10 | 2024-09-19 | Seagen Inc. | Methods of treating cancer with anti-tigit antibodies |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012019165A2 (en) * | 2010-08-05 | 2012-02-09 | Seattle Genetics, Inc. | Methods of inhibition of protein fucosylation in vivo using fucose analogs |
| KR20160093012A (ko) | 2013-11-05 | 2016-08-05 | 코그네이트 바이오서비시즈, 인코포레이티드 | 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물 |
-
2016
- 2016-12-02 SG SG11201804263PA patent/SG11201804263PA/en unknown
- 2016-12-02 EA EA201891340A patent/EA201891340A1/ru unknown
- 2016-12-02 CN CN201680071076.0A patent/CN108289903B/zh not_active Expired - Fee Related
- 2016-12-02 AU AU2016362993A patent/AU2016362993A1/en not_active Abandoned
- 2016-12-02 JP JP2018528650A patent/JP6906520B2/ja active Active
- 2016-12-02 MX MX2018006674A patent/MX385283B/es unknown
- 2016-12-02 US US15/781,256 patent/US20180353524A1/en not_active Abandoned
- 2016-12-02 WO PCT/US2016/064783 patent/WO2017096274A1/en not_active Ceased
- 2016-12-02 SG SG10202005298RA patent/SG10202005298RA/en unknown
- 2016-12-02 KR KR1020187017824A patent/KR20180086233A/ko not_active Withdrawn
- 2016-12-02 BR BR112018011261A patent/BR112018011261A2/pt not_active Application Discontinuation
- 2016-12-02 EP EP16871645.4A patent/EP3383404A4/en not_active Withdrawn
- 2016-12-02 CA CA3005997A patent/CA3005997A1/en not_active Abandoned
-
2018
- 2018-05-21 IL IL259479A patent/IL259479B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6906520B2 (ja) | 2021-07-21 |
| MX2018006674A (es) | 2018-11-09 |
| IL259479B (en) | 2022-03-01 |
| EA201891340A1 (ru) | 2018-11-30 |
| MX385283B (es) | 2025-03-18 |
| KR20180086233A (ko) | 2018-07-30 |
| CN108289903A (zh) | 2018-07-17 |
| WO2017096274A1 (en) | 2017-06-08 |
| BR112018011261A2 (pt) | 2018-11-21 |
| US20180353524A1 (en) | 2018-12-13 |
| CA3005997A1 (en) | 2017-06-08 |
| EP3383404A4 (en) | 2019-07-31 |
| IL259479A (en) | 2018-07-31 |
| JP2019501145A (ja) | 2019-01-17 |
| CN108289903B (zh) | 2021-08-03 |
| AU2016362993A1 (en) | 2018-07-12 |
| SG10202005298RA (en) | 2020-07-29 |
| EP3383404A1 (en) | 2018-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201906431UA (en) | Method for the treatment of thromboembolism | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201804268RA (en) | Conjugates of quaternized tubulysin compounds | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201900132QA (en) | Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy | |
| SG11201807977XA (en) | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor | |
| SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201805755SA (en) | Methods of administering hepcidin | |
| SG11201810940XA (en) | Methods of treating pancreatic cancer | |
| SG11201803643TA (en) | Virulence attenuated bacteria for treatment of malignant solid tumors | |
| SG11201901389XA (en) | Combination therapy with glutaminase inhibitors | |
| SG11201807526SA (en) | Combination therapy using a liv1-adc and a chemotherapeutic | |
| SG11201804597TA (en) | Vaccination with mica/b alpha 3 domain for the treatment of cancer | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |